Better together? Individual and synergistic effects of noneuphorigenic cannabinoids on visceral sensation
- 21 May 2025
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 392 (6) , 103593
Abstract
No abstract availableKeywords
Funding Information
- National Center for Complementary and Integrative Health (R01 AT012053)
- Penn State College of Medicine
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK122364)
This publication has 39 references indexed in Scilit:
- Cannabidiol and Cannabigerol, Nonpsychotropic Cannabinoids, as Analgesics that Effectively Manage Bone Fracture Pain and Promote Healing in MiceJournal of Bone and Mineral Research, 2023
- Abdominal pain is associated with an increased risk of future healthcare resource utilization in inflammatory bowel diseaseInternational Journal of Colorectal Disease, 2023
- The antinociceptive activity and mechanism of action of cannabigerolBiomedicine & Pharmacotherapy, 2023
- Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy‐induced peripheral neuropathyEuropean journal of pain, 2022
- Inflammatory Bowel Disease and Cannabis: A Practical Approach for CliniciansAdvances in Therapy, 2021
- Abdominal pain in quiescent inflammatory bowel diseaseInternational Journal of Colorectal Disease, 2020
- Opioid Analgesics Do Not Improve Abdominal Pain or Quality of Life in Crohn’s DiseaseDigestive Diseases and Sciences, 2019
- Profiles of Patients Who Use Marijuana for Inflammatory Bowel DiseaseDigestive Diseases and Sciences, 2018
- Cannabis Induces a Clinical Response in Patients With Crohn's Disease: A Prospective Placebo-Controlled StudyClinical Gastroenterology and Hepatology, 2013
- Pain and inflammatory bowel diseaseInflammatory Bowel Diseases, 2009